NTLA Stock — Intellia Therapeutics Inc.: Cash, EV, Pipeline

Share price

$12.14

Market cap

$1,701.1M

Cash

$437.8M

Enterprise value

$1,263.3M

Balance sheet

Cash	$437.8M
Debt	$0.0M
Net cash	$437.8M
Enterprise value	$1,263.3M
Basic shares	140.0M shares
Fully diluted shares	163.2M shares
Fully diluted market cap	$1,981.3M
Cash per share	$3.13

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NTLA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	nexiguran ziclumeran	Phase 3	Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease	—
Jan 12 - Feb 23	NTLA-2001	Phase 3	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	—
Sep 25 - Nov 6	REGV131	Phase 1/2	Hemophilia B	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

lonvo-z

Phase 3 · Active Modality: in vivo CRISPR-based gene editing therapeutic

Aliases lonvoguran ziclumeran, NTLA-2002

Target kallikrein B1 (KLKB1)

Partnerships Wholly owned.

Indications

Hereditary angioedema (HAE) (Phase 3)

Catalysts

— 2H 2026
— 1H 2027

Status note Wholly-owned investigational in vivo CRISPR therapeutic for HAE (inactivates the KLKB1 gene in the liver) delivered as a single IV infusion. Positive topline data from the global Phase 3 HAELO trial reported Apr 2026. Rolling BLA initiated Apr 2026; launch readiness activities underway.

nex-z

Phase 3 · Active Modality: in vivo CRISPR-based gene editing therapeutic

Aliases nexiguran ziclumeran, NTLA-2001

Target transthyretin (TTR)

Partnerships Co-development and co-promotion (Co/Co) agreement with Regeneron Pharmaceuticals for ATTR amyloidosis (2018). License and other agreements include up to $130M in contingent payments to Rewrite Therapeutics.

Indications

Transthyretin (ATTR) amyloidosis (Phase 3)

Catalysts

— 2H 2026

Status note Investigational in vivo CRISPR therapeutic for ATTR amyloidosis (inactivates the TTR gene in the liver) delivered as a single IV infusion via LNP technology. Phase 3 MAGNITUDE and MAGNITUDE-2 studies ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	nexiguran ziclumeran
Lead indication	Neuromuscular Disease
Lead phase	Phase 3
Active trials	6
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06672237	Phase 3	Recruiting	Sponsor	Intellia Therapeutics	REGN	Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease	—
NCT06128629	Phase 3	Recruiting	Sponsor	Intellia Therapeutics	REGN	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	—
NCT06634420	Phase 3	Active, not recruiting	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	—
NCT05120830	Phase 1/2	Active, not recruiting	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	—
NCT05697861	Not disclosed	Enrolling by invitation	Sponsor	Intellia Therapeutics	—	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy; Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy; Wild-Type Transthyretin Cardiac Amyloidosis	—
NCT06262399	Not disclosed	Enrolling by invitation	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	—
NCT06379789	Phase 1/2	Recruiting	Collaborator	REGN	REGN	Hemophilia B	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Intellia Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	930,232	+930,232	0.08%	2026-08-14
ADAR1 Capital Management	0	-19,517	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NTLA — Intellia Therapeutics Inc.